Kunal Mahajan

Dr. Kunal Mahajan

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2024 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
RPRaman Puri
Raman Puri
MBManish Bansal
Manish Bansal
VMVimal Mehta
Vimal Mehta
PDP. Barton Duell
P. Barton Duell
Nathan D. WongNathan D. Wong
Nathan D. Wong
JMJ.C. Mohan
J.C. Mohan
In 2016, the Lipid Association of India (LAI) developed a cardiovascular risk assessment algorithm and defined low-density lipoprotein cholesterol (LDL-C) goals for prevention of atherosclerotic cardiovascular disease (ASCVD) in Indians. The recent refinements in the role of various risk factors and subclinical atherosclerosis in prediction of ASCVD risk necessitated updating the risk algorithm and treatment goals. The LAI core committee held twenty-one meetings and webinars from June 2022 to July 2023 with experts across India and critically reviewed the latest evidence regarding the strategies for ASCVD risk prediction and the benefits and modalities for intensive lipid lowering. Based on the expert consensus and extensive review of published data, consensus statement IV was commissioned. The young age of onset and a more aggressive nature of ASCVD in Indians necessitates emphasis on lifetime ASCVD risk instead of the conventional 10-year risk. It also demands early institution of aggressive preventive measures to protect the young population prior to development of ASCVD events. Wide availability and low cost of statins in India enable implementation of effective LDL-C lowering therapy in individuals at high risk of ASCVD. Subjects with any evidence of subclinical atherosclerosis are likely to benefit the most from early aggressive interventions. This document presents the updated risk stratification and treatment algorithm and describes the rationale for each modification. The intent of these updated recommendations is to modernize management of dyslipidemia in Indian patients with the goal of reducing the epidemic of ASCVD among Indians in Asia and worldwide.

1 January 2018 in Indian Heart Journal
Verified
Journal Article
Open access
KMKunal Mahajan
Kunal Mahajan
ABAditya Batra
Aditya Batra

1 December 2017 in International Journal of Cardiology
Verified
Journal Article
Closed access
KMKunal Mahajan
Kunal Mahajan
PNPrakash Chand Chand Negi
Prakash Chand Chand Negi
RMRajeev Merwaha
Rajeev Merwaha
NMNitin Mahajan
Nitin Mahajan
VCVivek Chauhan
Vivek Chauhan
SASanjeev Asotra
Sanjeev Asotra

1 December 2018 in Global Heart
Verified
Journal Article
Closed access
PNPrakash Chand Negi
Prakash Chand Negi
KMKunal Mahajan
Kunal Mahajan
VRVivek Rana
Vivek Rana
SSSachin Sondhi
Sachin Sondhi
NMNitin Mahajan
Nitin Mahajan
DSDavinder Pal Singh
Davinder Pal Singh
Despite the high prevalence of rheumatic heart disease (RHD) in developing countries such as India, data on characteristics, complications, and treatment practices are lacking. The HP-RHD (Himachal Pradesh Rheumatic Heart Disease) registry aimed at reporting these parameters in patients with RHD from a northern state of India. A total of 2,005 consecutive patients of RHD were enrolled over a period of 6 years (2011 to 2016) in the present study. The clinical characteristics, complications, and treatment practices were systematically recorded. The mean age for patients with RHD was 40.3 ± 14.3 (range 5 to 83 years). RHD predominantly affected females (72.3%) and population from rural background (92%). Multivalvular involvement was frequent (43.2%), mitral valve was the commonest affected valve (83.3%). The majority of the patients had moderate-to-severe valvular dysfunction (69.3%). Mitral and tricuspid valve involvement was more frequent in female subjects compared with more frequent aortic valve involvement in male subjects (p < 0.001). The major adverse cardiovascular events were recorded in 23.4% patients at the time of registry and comprised mainly advanced heart failure (15.6%), peripheral embolism (4.1%), and stroke (3.9%). The independent risk determinants of major adverse cardiovascular events (were advanced age (odds ratio [OR]: 1.01; 95% confidence interval [CI]: 1.00-1.02), severe mitral stenosis (OR: 1.73; 95% CI: 1.34-2.20), severe tricuspid regurgitation (OR: 2.11; 95% CI: 1.48-3.02), presence of pulmonary artery hypertension (OR: 1.33; 95% CI: 1.04-1.69), and atrial fibrillation (OR: 1.64; 95% CI: 1.28-2.11). Evidence-based use of oral anticoagulant therapy was documented in 77.7% of high-risk patients. Only 28.5% of study population was receiving secondary prophylaxis. Complications in patients with RHD increase with age and worsening valvular dysfunction. Programs focused on early detection and evidence-based management will assist in improving outcomes.

1 July 2020 in Medical Journal Armed Forces India
Verified
Journal Article
Closed access
KMKunal Mahajan
Kunal Mahajan
KCK.SArat Chandra
K.SArat Chandra

7 June 2024 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
KMKunal Mahajan
Kunal Mahajan
RPRaman Puri
Raman Puri
PDP. Barton Duell
P. Barton Duell
DDDeep Dutta
Deep Dutta
RYRahul Yadav
Rahul Yadav
Nathan D. WongNathan D. Wong
Nathan D. Wong